This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niedrig, M.
Right arrow Articles by Sonnenberg, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niedrig, M.
Right arrow Articles by Sonnenberg, K.

Next Article 

Clinical and Vaccine Immunology, February 2008, p. 177-181, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00078-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus{triangledown}

Matthias Niedrig,1* Oliver Kürsteiner,2 Christian Herzog,2 and Karen Sonnenberg3

Robert Koch Institut, Nordufer 20, 13353 Berlin, Germany,1 Berna Biotech AG, a Crucell Company, Rehhagstrasse 79, 3018 Berne, Switzerland,2 Euroimmun AG, Seekamp 31, 23560 Luebeck, Germany3

Received 12 February 2007/ Returned for modification 29 March 2007/ Accepted 8 November 2007

The first commercial indirect immunofluorescence assay (IFA) using Euroimmun Biochip technology was evaluated for the serodiagnosis of immunoglobulin G (IgG) and IgM antibodies against yellow fever virus (YFV) and was compared with the plaque reduction neutralization test (PRNT), which is currently the gold standard test for YFV. An overall correlation between the tests of 98.7% was established based on the analysis of 150 sera from individuals after vaccination with the 17D yellow fever vaccine. The sensitivity and specificity, calculated using the 150 sera from vaccinees and 150 sera from healthy blood donors, were 95% and 95%, respectively, for the IgG IFA and 94% and 97% for the IgM IFA. Antibody titers found in the PRNT correlated poorly with the IgM and IgG titers detected by IFA. The analysis of preexisting heterologous flaviviral immunity revealed the presence of antibodies reactive with YFV, tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and dengue virus serotypes 1 to 4 in 20 out of the 150 vaccinees. The indirect IFA showed that nine of these individuals with previous flaviviral exposure who received 17D vaccine failed to produce detectable IgM antibodies. Despite this preexisting immunity, all vaccinees developed protective immunity as detected by PRNT and anti-YFV IgG antibodies as detected by IFA. The high specificity and sensitivity of the IFA make it a useful tool for rapid diagnosis of yellow fever during outbreaks, for epidemiological studies, and for serosurveillance after vaccination.

* Corresponding author. Mailing address: Robert Koch Institut, Nordufer 20, 13353 Berlin, Germany. Phone: 49 30-4547-2370. Fax: 49 30-4547-2625. E-mail: niedrigm{at}rki.de

{triangledown} Published ahead of print on 28 November 2007.

Clinical and Vaccine Immunology, February 2008, p. 177-181, Vol. 15, No. 2
1071-412X/08/$08.00+0     doi:10.1128/CVI.00078-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»